Study of Initial Steroid Treatment in Young Children With Nephrotic Syndrome
Status:
Withdrawn
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
This study is a multicentric, prospective, randomized, double blind, placebo controlled trial
compared the efficacy of 6 months vs. 3 months of initial prednisolone therapy in decreasing
the incidence of FRNS with steroid-sensitive nephrotic syndrome in children age 1 year up to
6 years. Three months tapering prednisolone or placebo are administrated follow by open-label
3 months standard prednisolone therapy.The cumulative incidence of FRNS and adverse events
for one year were evaluated in the 3-month and 6-month groups.